BD BBL Sensi Disc Ciprofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231657®and 231658®
Published February 14, 2024 · Recall initiated: January 8, 2024
Summary
FDA records medical device Class II recall Z-1027-2024, published February 14, 2024 and initiated January 8, 2024. Recalling firm: Becton Dickinson & Co.; Status: Ongoing; Reported quantity: 2,363,168 total units; Lot: Catalog No. 231657® UDI-DI 00382902316572 Lots 1060926 1279842 2028533 2091948 2301402 3214964 3248370; Catalog No. 231658® UDI-DI 30382902316580 Lots 1335458 2336475 3062295 3093427 3163048 3214964 3248370 0344330 1007112 1060926 1127037 1279842 1335457 2028533 2028547 2091948 2091980 2301402 2336474. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Becton Dickinson & Co.
- Distributor
- Domestic distribution nationwide. International distribution worldwide.
- Lot
- Catalog No. 231657® UDI-DI 00382902316572 Lots 1060926 1279842 2028533 2091948 2301402 3214964 3248370; Catalog No. 231658® UDI-DI 30382902316580 Lots 1335458 2336475 3062295 3093427 3163048 3214964 3248370 0344330 1007112 1060926 1127037 1279842 1335457 2028533 2028547 2091948 2091980 2301402 2336474
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDABD Phoenix Panel NMIC-312. Catalog Number: 449082.October 21, 2026
- FDABD Phoenix Panel NMIC-306. Catalog Number: 449292.October 21, 2026
- FDABD GasPak EZ CO2 Pouch System. Catalog Number: 260684. for microbiologic useMay 6, 2026
- FDABD GasPak EZ Campy Pouch System. Catalog Number: 260685. for microbiologic useMay 6, 2026
- FDABD BBL Sensi Disc Chloramphenicol- 30 ug, used for semi-quantitative in vitro susceptibility testing. CatalogFebruary 14, 2024
- FDABD BBL Sensi Disc Clarithromycin- 15 ug, used for semi-quantitative in vitro susceptibility testing. CatalogFebruary 14, 2024
Questions about this recall
Was BD BBL Sensi Disc Ciprofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231657®and 231658® recalled?
Yes. FDA published recall Z-1027-2024 on February 14, 2024. Reported hazard: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
What should I do if I have this product?
Voluntary: Firm initiated · Letter